Gastrointestinal Cancer

Although chemotherapy combinations remain standard first-line therapy for advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer, strategies for progressive disease have shifted to include antiangiogenic agents and immunotherapy.

Gastrointestinal oncology experts highlight what they are most excited for at the upcoming International Society of Gastrointestinal Oncology 16th Annual Gastrointestinal Oncology Conference.

Emil Israel Cohen, MD, an assistant professor at Medstar Georgetown University Hospital, discusses the criteria for ablation therapy in patients with liver cancer.

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses PARP inhibition in patients with pancreatic cancer.

Patients with metastatic colorectal cancer who harbored BRAF non-V600, RAS-dependent mutations were more likely to respond to anti-EGFR therapy versus those with BRAF non-V600, RAS-independent mutations.

Gulam A. Manji, MD, PhD, discusses treatment for patients with colorectal cancer who harbor NTRK fusions.

The International Society of Gastrointestinal Oncology, a not-for-profit global educational organization committed to gastrointestinal oncology, will host the 16th Annual Gastrointestinal Oncology Conference from Oct. 10-11, 2019 at the Hilton Crystal City in Arlington, Virginia.

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses where future research should focus in metastatic colorectal cancer.

We traveled to Denver, Colorado, for a State of the Science Summit™ on Gastrointestinal Cancers, which featured insights from University of Colorado and Rocky Mountain Cancer Centers faculty.

Two distinct subtypes of nonfunctional pancreatic neuroendocrine tumors could help prognosticate risk of recurrence following surgery.

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses future directions in metastatic colorectal cancer (mCRC).

Three months of adjuvant oxaliplatin-based therapy in patients with high-risk, stage II colorectal cancer was found to be inferior to 6 months of treatment.

Gulam A. Manji, MD, PhD, discusses the difference between right- and left-sided tumors in colorectal cancer and the appropriate treatment for right-sided tumors based on a subgroup analysis.

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses an investigational immunotherapy combination being explored in patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.